The case for & against
Bull & Bear analysis
Bullish
Alvotech (NASDAQ: ALVO) is a biopharmaceutical company specializing in the development and commercialization of high-quality biosimilars. The firm operates within the fast-growing biosimilars segment, particularly in the therapeutic area of autoimmune and inflammatory diseases. Positioned as a prominent player, Alvotech has a solid portfolio of products in various stages of development. The company is actively leveraging its innovative manufacturing and regulatory capabilities to navigate a competitive landscape and expand patient access to biologics globally.
Bull says
- ↑Q1 2025 revenue reached $110M, up 784% YoY on Humira/Stelara biosimilars.
- ↑FDA closed inspection with VAI classification; resubmission planned in Q2 2026.
- ↑Pipeline exceeds 30 candidates, addressing a $185B biosimilars market; Humira share to hit 50%.
- ↑Fujifilm partnership expands manufacturing capacity for future launches.
- ↑Q1 2025 adjusted EBITDA of $21M turned positive; product margins at 41%.
- ↑Effective use of leverage fuels growth; analysts raising earnings estimates.
Bear says
- ↓Q1 2026 revenue declined 20% amid production slowdowns for facility upgrades.
- ↓Short interest up 17% and analysts label it a "Moderate Sell."
- ↓Operating cash flow was negative $25M in Q1 2026, net debt at $1.58B.
- ↓Profitability remains challenged with negative adjusted EBITDA trend and margin pressure.
- ↓FDA demands 180+ observations, delaying resubmissions and regulatory approvals.
- ↓High revenue expectations ($650–700M) risk a value trap if unmet.
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-20-2026bullish
Transcript signals
Bull points
- Overall, our performance in the first half of the year was strong, both in terms of revenue growth margin expansion, and continued cash flow robustness.
- Revenues continue on a strong momentum, and we're up 30% at $306 million, compared to $236 million in the first half of 2024.
- we do expect a similar dynamic to occur this year towards the latter part of the year.
Bear points
- we do expect product revenues as well as milestone revenues to soften in Q3, followed by a much stronger result in Q4.
- Adjusted EBITDA in the first half was $54 million, compared to $64 million during the same period in the prior year and adjusted EBITDA in Q2 was $18 million versus $102 million during Q2 last year.
- pricing in Stellar market is quite competitive, with some of our competitors offering pricing that we believe are not sustainable in the long run.
Read full transcript analysis ›